We are live on
!
Find out more
QC
Quadrature Capital Portfolio holdings
AUM
$8.4B
1-Year Est. Return
63.34%
This Fund
S&P 500
This Quarter
Est. Return
+10.07%
1 Year Est. Return
+63.34%
3 Year Est. Return
+138.13%
5 Year Est. Return
+102.94%
10 Year Est. Return
+462.02%
AUM
$8.4B
AUM Growth
-$1.39B
(-14%)
Cap. Flow
-$1.42B
Cap. Flow
% of AUM
-16.87%
Top 10 Holdings %
Top 10 Hldgs %
24.29%
Holding
2,005
New
788
Increased
262
Reduced
256
Closed
692
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$241M |
| 2 |
Microsoft
MSFT
|
+$174M |
| 3 |
SAP
SAP
|
+$166M |
| 4 |
CrowdStrike
CRWD
|
+$137M |
| 5 |
Intel
INTC
|
+$128M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SNDK
Sandisk
SNDK
|
+$307M |
| 2 |
Canadian National Railway
CNI
|
+$187M |
| 3 |
GE Vernova
GEV
|
+$183M |
| 4 |
Netflix
NFLX
|
+$156M |
| 5 |
Eli Lilly
LLY
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.56% |
| 2 | Financials | 13.23% |
| 3 | Consumer Discretionary | 9.27% |
| 4 | Healthcare | 8.86% |
| 5 | Industrials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Aligos Therapeutics
ALGS
$25.2M
| $80.4K | ﹤0.01% |
+10,822
| New | +$82.1K |
|
1252
Black Diamond Therapeutics
BDTX
$101M
| $79.8K | ﹤0.01% |
+37,474
| New | +$89.1K |
|
1253
Entravision Communication
EVC
$983M
| $79.1K | ﹤0.01% |
+26,640
| New | +$81.7K |
|
1254
Shattuck Labs
STTK
$710M
| $78K | ﹤0.01% |
+12,134
| New | +$57.6K |
|
1255
Zentalis Pharmaceuticals
ZNTL
$308M
| $78K | ﹤0.01% |
33,332
-104,236
| -76% | -$269K |
|
1256
PMV Pharmaceuticals
PMVP
$66.1M
| $75.9K | ﹤0.01% |
61,174
+42,746
| +232% | +$54.4K |
|
|
AUTL
1257
Autolus Therapeutics
AUTL
$386M
| $75.5K | ﹤0.01% |
54,733
+12,392
| +29% | +$18.8K |
|
1258
Alto Ingredients
ALTO
$360M
| $75.3K | ﹤0.01% |
+15,551
| New | +$49.3K |
|
1259
Caribou Biosciences
CRBU
$156M
| $75.2K | ﹤0.01% |
39,556
-119,761
| -75% | -$206K |
|
1260
Compass Therapeutics
CMPX
$373M
| $73.2K | ﹤0.01% |
13,845
+1,552
| +13% | +$8.96K |
|
|
SFIX
1261
Stitch Fix
SFIX
$478M
| $73.2K | ﹤0.01% |
+22,105
| New | +$90.2K |
|
|
DGXX
1262
Digi Power X Inc
DGXX
$360M
| $72.8K | ﹤0.01% |
35,868
-328,829
| -90% | -$861K |
|
1263
Acacia Research
ACTG
$450M
| $72.5K | ﹤0.01% |
+15,079
| New | +$63.5K |
|
1264
Aura Biosciences
AURA
$729M
| $71.4K | ﹤0.01% |
+10,667
| New | +$61.2K |
|
1265
Quad
QUAD
$430M
| $71K | ﹤0.01% |
10,743
-5,199
| -33% | -$33.6K |
|
1266
Biomea Fusion
BMEA
$90.4M
| $70.6K | ﹤0.01% |
46,162
-23,770
| -34% | -$31.2K |
|
|
RWT
1267
Redwood Trust
RWT
$616M
| $70.6K | ﹤0.01% |
+12,579
| New | +$72.9K |
|
1268
Community Health Systems
CYH
$385M
| $69.7K | ﹤0.01% |
+23,713
| New | +$76.8K |
|
|
CRDL
1269
Cardiol Therapeutics
CRDL
$136M
| $64.6K | ﹤0.01% |
+47,887
| New | +$49.1K |
|
1270
Pliant Therapeutics
PLRX
$67.5M
| $64.2K | ﹤0.01% |
50,981
-46,910
| -48% | -$59.2K |
|
|
BTQ
1271
BTQ Technologies Corp
BTQ
$479M
| $61.3K | ﹤0.01% |
+22,976
| New | +$81K |
|
1272
Inhibikase Therapeutics
IKT
$366M
| $60.6K | ﹤0.01% |
+36,062
| New | +$64K |
|
1273
3D Systems Corp
DDD
$420M
| $59.3K | ﹤0.01% |
31,527
-18,228
| -37% | -$40.5K |
|
1274
Equillium
EQ
$157M
| $57.5K | ﹤0.01% |
+28,760
| New | +$47.3K |
|
1275
Alvotech
ALVO
$1.03B
| $56.3K | ﹤0.01% |
+16,412
| New | +$72.1K |
|
Similar funds
NW
AAF
VA
FT
MWM
GGHC
DM
GRQ
Quadrature Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Quadrature Capital held 2,005 positions worth $8.4B, down 14% from $9.8B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Quadrature Capital withdrew a net $1.42B in Q1 2026, closing 692 positions and reducing 256 holdings. Its most notable exit was Netflix, an estimated $156M position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 24% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Quadrature Capital opened a new position in SPDR Gold Trust worth $231M.
- Quadrature Capital's largest Q1 2026 buy was SPDR Gold Trust: 537,107 shares worth $231M.
- Quadrature Capital added most to SAP in Q1 2026, an estimated $166M increase.
- Quadrature Capital's biggest Q1 2026 reduction was Sandisk, cutting an estimated $307M.
- Quadrature Capital fully exited Netflix in Q1 2026, selling an estimated $156M.
- Quadrature Capital's ten largest holdings make up 24% of its $8.4B portfolio in Q1 2026.
- Quadrature Capital opened 788 new positions and closed 692 in Q1 2026.
- Quadrature Capital's portfolio value fell 14% quarter-over-quarter to $8.4B.
Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.